NHS England to fund HIV treatment Rezolsta

NHS England will provide crucial funding for Janssen’s once-daily, fixed-dose combination of darunavir and the pharmacoenhancer, cobicistat, called Rezolsta. Rezolsta is indicated for use in combination with other antiretroviral medications for treating adults with HIV-1, whose virus does not carry darunavir resistance-associated mutations. Meaning clinicians across England will be able to routinely prescribe darunavir –

Continue Reading

Scotland Unveils £100-million Cancer Strategy

Scotland has unveiled a £100-million strategy to tackle cancer by improving prevention, detection, diagnosis, treatment and after care for those affected by the disease. The Scottish government has stated its strategy; “Beating Cancer: Ambition and Action”, which contains more than 50 actions, which will serve as the future blueprint for cancer care in the country over the

Continue Reading

Three New Drugs Approved for Use on NHS Scotland

Three new medicines have been granted approval by cost regulators for use on NHS Scotland. The new treatments will offer options to patients for breast cancer, prostate cancer and heart failure. The Scottish Medicines Consortium has now accepted use of Eisai’s Halaven (eribulin) for the treatment of advanced breast cancer in those patients who have

Continue Reading

NHS to help design 10 ‘healthy new towns’ to Tackle Challenges such as Obesity and Dementia

NHS England will be helping to design 10 ‘healthy new towns’ across the country in collaboration with Public Health England, with the aim of developing new solutions to key healthcare challenges within the country such as obesity and dementia. The plan stipulates more than 76,000 new homes with potential capacity for around 170,000 residents will

Continue Reading

NICE Increases Access to Ankylosing Spondylitis Therapy

Cost regulators for the NHS England and Wales have expanded treatment options for patients with ankylosing spondylitis. NICE has now published guidelines recommending TNF-alpha inhibitors -adalimumab (AbbVie’s Humira), certolizumab pegol (UCB Pharma’s Cimzia), etanercept (Pfizer’s Enbrel), golimumab (MSD’s Simponi) and infliximab (MSD’s Remicade, Napp Pharmaceuticals’ Remsima, and Hospira’s Inflectra) – for the condition. The drugs

Continue Reading